The research clusters of Heidelberg (Germany), Leuven (Belgium) and Cambridge (England) have launched the “Health Axis Europe” initiative, which is aimed at cross-leveraging their innovation resources and working together to increase their international competitiveness by facilitating and coordinating EU-funded collaborative R&D projects, cross-border VC investment and syndication and the cross-border exchange of scientists.
GENOVAC GmbH has announced that it has entered into a research collaboration with ESBATech, a subsidiary of Alcon Biomedical, for the generation of antibodies for use in the field of ophthalmology. Under the terms of the agreement, GENOVAC will use its genetic immunisation technology to generate high-affinity antibodies against molecular targets identified by ESBATech.
BD Diagnostics, a segment of BD (Becton, Dickinson and Company), and Lonza Group Ltd announced today that they have entered into an exclusive licensing and collaboration agreement for Lonza to commercialize its microCompass™ molecular assays on the BD MAX™ System.
Strasbourg, France based NovAliX SAS today announced that it has entered into a definitive agreement to acquire a majority interest in Graffinity Pharmaceuticals GmbH of Heidelberg, Germany, a leading fragment based drug discovery services company. Financial details of the transaction were not disclosed.
HEIDELBERG, October 15, 2009 — Graffinity Pharmaceuticals GmbH announced today that it has entered into a drug discovery research collaboration with Genentech, Inc, a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY). With this collaboration Genentech will gain access to Graffinity’s proprietary, fragment-based drug discovery technology.
Boehringer Ingelheims research cooperation with the two biotech companies Evotec and Orexo is making good progress. Swedish Orexo AB recently announced that it has extended its three-year research cooperation with Boehringer Ingelheim for another year up to November 2009.
In order for a company to make efficient use of its potential and its specific skills it must focus on its own core competences and on the cooperation with other companies that have supplementary skills. This is all the more important in economically difficult times when investors and banks tend to shy away from investments. The implementation of cooperations between companies raises a number of general issues as well as specific issues relating to drug law regulations.
Lipid Therapeutics GmbH and Dr. Falk Pharma GmbH announced on 30th, September, that they have entered into a co-development and licensing agreement for LT-02. Under the terms of the agreement, Dr. Falk Pharma will receive exclusive access to the European rights to Lipid Therapeutics’ lead product LT-02 for the treatment of ulcerative colitis. Ulcerative colitis is a severe inflammation of the colon affecting more than one million people worldwide.
Phenex Pharmaceuticals AG (Phenex) today announced the achievement of a milestone in the collaboration with Janssen Biotech, Inc. (Janssen), which triggers a 6 M US$ payment by Janssen. In late 2012, Phenex and Janssen entered into a research collaboration on RORgt with a view to develop new therapeutic approaches for chronic inflammatory and autoimmune diseases.
Seven European research institutions and GATC Biotech have formed a consortium providing cutting-edge training in the scientific study of the human past. The BEAN (Bridging the European and Anatolian Neolithic) Initial Training Network has been awarded four years of funding from the European Commission through the Marie Curie Actions program. It is a new multinational and multidisciplinary Marie Curie Research initiative exploring the origins of European agriculture.
(Lake Constance/Stuttgart) – BioLAGO e.V. and BIOPRO Baden-Württemberg GmbH are working together on the “DiagNeeds” project to bring hospitals and medical professionals closer to diagnostics providers in order to facilitate the development of new diagnostic procedures. There will be special focus on topics that are currently of major interest in the field of diagnostics, including liquid biopsies, companion diagnostics, point-of-care diagnostics and biomarkers.
Several biotechnology and medical technology companies from Baden-Wüttemberg and Singapore interested in international cooperation met in Stuttgart on 19th November 2010. The event was organised by SRING Singapore Enterprise and BIOPRO Baden-Württemberg GmbH.
BIOPRO Baden-Württembergs business development activities have led to the establishment of a new distribution partnership between Heidelberg-based Medicyte GmbH and Dutch Westburg BV. When BIOPRO searches for international partners for Baden-Württemberg companies the state agency often makes use of its international network partners and in this case BIOPROs contact with the Netherlands Business Support Office Stuttgart NBSO brought the desired results.
At MEDTEC Europe 2012, the leading medical platform in Europe held in Stuttgart from 13th to 15th March 2012, the three life sciences organisations BIOPRO Baden-Württemberg GmbH, Health Technology Cluster – Clusterland Oberösterreich GmbH and Human.technology Styria GmbH signed a “Memorandum of Understanding (MoU”) to seal their future cooperation.
In a Memorandum of Understanding signed on march 4th, the European Commission (EC) and the European Molecular Biology Laboratory (EMBL) formalise their desire to maintain and further develop their cooperation.
It is also in the interest of small companies to look beyond their national borders: biotechnology and medical technology specialists in neighbouring European countries offer excellent prospects to German companies – and vice versa. Regional life sciences networks help establish and intensify contacts and collaborative activities between international partners.
On Tuesday 23 March, the Tübingen-Reutlingen Technology Park (TTR) was the destination for entrepreneurs keen to find out more about the FASILIS EU project. This transnational pilot project helps small and medium-sized businesses benefit from the research, infrastructure and service portfolios of the participating European regions. The cooperation forum uses a voucher system to promote innovation and the establishment of new business relationships. In Germany, BioRegio STERN Management GmbH distributes these vouchers to companies in the life sciences sector in the STERN BioRegion.
Representatives from companies and research institutes based in the STERN BioRegion met metalworking and surface treatment specialists in France. The collaboration between BioRegio STERN Management GmbH and Ple Technologique de Haute-Champagne PTHC opens up the way for making new contacts sharing innovative ideas and exploring cooperation options.
At the recent Science meets Business Day four tandem teams of the German BioValley Platform presented their projects. These will be introduced in two articles. The first article focuses on natural substances with a pharmaceutical potential.
The leaders of the two countries research policy groups met in the French capital to discuss strategies on how to cope with challenges that are faced by both countries in the field of research. Several Agreements signed at the end of the Forum are the basis of strategic partnerships.
The traditionally strong research into leukaemia at Ulm University is to be further strengthened by the German Research Foundation (DFG). The DFG will fund the new cooperative research centre (SFB) with 8.8 million euros for a period of four years, starting in July 2012. The SFB 1074 “Experimental Models and Clinical Translation in Leukaemias” aims to bring together basic research-oriented and clinical research.
In the second article in the series on the platforms successful cooperations BioValley presents an encouraging approach for improving the quality of life of severely ill cancer patients and the successful establishment of an industrial biochip platform.